🇺🇸 FDA
Pipeline program

Pimavanserin

ACP-103-055

Phase 3 small_molecule terminated

Quick answer

Pimavanserin for Adjunctive Treatment of Major Depressive Disorder is a Phase 3 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 3 ClinicalTrials.gov record(s).

Program details

Company
ACADIA PHARMACEUTICALS INC
Indication
Adjunctive Treatment of Major Depressive Disorder
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials